This prospective uncontrolled study evaluated the effect of low-dose adjunctive perampanel therapy (4 mg/day for 3 months) on the sleep-wake cycle and daytime somnolence in adult patients (n = 10) with focal seizures. A > 50% reduction in the number of seizures was reported in 80% of the study patients; treatment had no significant effect on any sleep parameters as evident by the Maintenance of Wakefulness Test, Pittsburgh Sleep Quality Index and Epworth Sleepiness Scale scores. Two patients reported dizziness with treatment. In conclusion, low-dose perampanel may improve seizure control without affecting the sleep characteristics or daytime somnolence in patients with epilepsy.
Keywords: AEs, adverse events; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ASDs, anti-seizure drugs; Actigraphy; Antiepileptic drugs; CNS, central nervous system; Daytime somnolence; ESS, Epworth sleepiness scale; Epilepsy; MWT, maintenance wakefulness test; Maintenance of wakefulness test; PSQI, Pittsburgh sleep quality index; REM, rapid eye movement; Sleep.